Evidence map›Paper›PMID 19618992›Full record

Trial reportExpert opinion on pharmacotherapy2009

Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.

Fabio Galvano, Giovanni Li Volti, Michele Malaguarnera, Teresio Avitabile, Tijana Antic, Marco Vacante, Mariano Malaguarnera

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Expert opinion on pharmacotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03696940 (Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03696940 phase3unknown statusstarted 2018, after this paper: background citation

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Ran2018Enrolled120Registered outcomes6Posted comparisons0ConditionsCardiovascular Risk Factor, DyslipidemiasArmsAtorvastatin 10mg, L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
PMID 27046161PMID 25537708PMID 24793440PMID 24793441PMID 24793443PMID 16034009PMID 26939026PMID 17039901PMID 23190071PMID 19604523PMID 25915661PMID 16384561other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Overcoming Challenges With Statin Therapy.Journal of the American Heart Association · 2016
    Review
  15. How effective are antioxidant supplements in obesity and diabetes?Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2015
    Review
  16. Article
  17. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine.Translational research : the journal of laboratory and clinical medicine · 2013
    Review
  18. Lipoprotein(a) in cardiovascular diseases.BioMed research international · 2013
    Review
  19. Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington's disease patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Fabio GalvanoUniversity of Catania, Department of Biological Chemistry, Medical Chemistry and Molecular Biology, Viale A. Doria 6, 95125 Catania, Italy.
Giovanni Li Volti
Michele Malaguarnera
Teresio Avitabile
Tijana Antic
Marco Vacante
Mariano Malaguarnera
University of Catania · ITWeatherford College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients. PATIENTS/

methodsIn this double-blind, randomized clinical trial, 75 patients were assigned to one of two treatment groups for 4 months. Group A received simvastatin monotherapy; group B received L-carnitine and simvastatin. The following variables were assessed at baseline, after washout and at 1, 2, 3 and 4 months of treatment: body mass index, fasting plasma glucose, glycated hemoglobin, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, Apolipoprotein A1, Apo B, lipoprotein(a) and apoprotein(a).

resultsAt the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05).

conclusionsThe coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100.

Indexed as

Apoprotein(a)Blood GlucoseBody Mass IndexCarnitineCholesterol, HDLCholesterol, LDLDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationDyslipidemiasFemaleGlycated HemoglobinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipoprotein(a)Apoprotein(a)Blood GlucoseCarnitineCholesterol, HDLCholesterol, LDLGlycated HemoglobinHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipoprotein(a)SimvastatinTriglycerides

Identifiers

PMID19618992
OpenAlexW1965068342

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.